GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront
GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront
本文は利用できません。元の情報源をご確認ください。
GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront